Hoth Therapeutics Inc (HOTH) Stock Price, Quote & News

Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for th...

Industry: Biotechnology

Sector: Healthcare

Phone: (646) 756-2997

Website: hoththerapeutics.com

Address:

1177 Avenue of the Americas, Suite 5066 5th Floor, New York, United States

4trax Aug. 17 at 7:07 PM

$HOTH when is the next catalyst?

0 · Reply

canadianpennystockhunter Aug. 15 at 5:09 PM

$ADN $HOTH @WallStreetReporter Dont sleep on these!!!!!!!! Do the research, and get in while you can. These are solid companies, with strong CEOs behind them. Nothing is guaranteed in the market, but you should feel at ease after you see what these companies have to offer. Buy, buy, buy baybay!!!!!!!!!

0 · Reply

onestudy Aug. 15 at 4:23 PM

$SILO Big momentum. Louisiana bill advancing to study psychedelics for vets. $SILO is awaiting PTSD drug dosing results (FDA) — due ≤4 weeks. Recently $SILO got engaged with U.S. Department of Veterans Affairs via $HOTH which already started a VA study.

0 · Reply

PSM_EmpowerTrading Aug. 15 at 4:11 AM

🌅🌅 watchlist part 2 ✅️ $KULR mid 6.50 support, if above 7, have potential to 7.40/.50 ✅️ $HCTI low 4 support, if above 4.30, have potential to 4.65/.75 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $GFAI $HOTH still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

1 · Reply

PSM_EmpowerTrading Aug. 14 at 7:01 PM

⏳️⌛️ Potential swing ideas 💡 ✅️ $SILO recently acquired digital assets from MAVS holdings, have until 12/24/25 to regain Nasdaq compliance by bringing price above $1 for 10 consecutive days, recently partnered with $HOTH for obesity treatment, upcoming catalyst: 1) preclinical data on SPC-15, intranasal therapy (5-HT4 receptor agonist) aimed at PTSD and anxiety, leveraging a fast-acting nose-to-brain delivery mechanism in Q3, ✅️ $HOTH recently entered joint venture with $SILO Pharma to commercialize VA-invented obesity Drug, recent data demonstrated significant reduction in tumor growth, announced patent to develop anti-obesity treatments with US Depart. Of Veterans Affairs, also previously purchased up to $1M of $BTC.X as treasury reverse asset, upcoming catalysts: 1) IND filing for HT-KIT, which recently announced positive data, suppressing tumor growth in preclinical models, expected to submit early 2026, D. Boral capital price target $5, HC Wainwright price target $4

0 · Reply

PSM_EmpowerTrading Aug. 14 at 1:18 PM

🌅🌅 watchlist part 2 ✅️ $SNOA low 6 support, if above 6.50, have potential to 7/7.30, small float, launches hypochlorous acid (HOCI)-based diaper trash in 3,600 $WMT stores and online ✅️ $DLPN low 1.20 support, if above 1.60, have potential to 1.85/.95, expanding services with launch of Tastemakers division ✅️ $XOS low 4.30 support, if above 4.60, have potential to 5/5.30, up on earnings ✅️ FOSL ideal if above 2 support, if above 2.30, have potential to 2.50/.60, up on earnings 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ OPAD $HOTH still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

PSM_EmpowerTrading Aug. 14 at 4:23 AM

🌅🌅 watchlist part 2 ✅️ $XOS low 4 support, if above 4.30, have potential to 4.70/.80, up on earnings ✅️ $FOSL low 2 support, if above 2.30, have potential to 2.50/.60, up on earnings ✅️ $IVF ideal if above 2 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $OPAD $HOTH still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

2 · Reply

Thunder000 Aug. 13 at 3:00 PM

$CGTX $HOTH $MIRA $SNSE Please consider come join $IBRX after you’ve done here. Great news and way way undervalued “ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy”

1 · Reply

Pratik2024 Aug. 13 at 2:42 PM

$AREC $GFAI $HOTH $KULR $MWYN Which one to load now?

1 · Reply

PSM_EmpowerTrading Aug. 13 at 1:07 PM

🌞🌞 watchlist part 2 ✅️ $GBIO low 5 support, if above 5.50, have potential to 5.90/6, up on earnings ✅️ $SWAG mid 1.50 support, if above 2, have potential to 2.40/.50 ✅️ $HRTX 1.40 support, if above 1.55, have potential to 1.70/.80 ✅️ NIVF low 2 support, if above 2.40, have potential to 2.80/.90 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $HOTH $NUBV still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe

Jul 22, 2025, 8:19 AM EDT - 26 days ago

Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

Jun 25, 2025, 8:27 AM EDT - 7 weeks ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

SILO

Jun 24, 2025, 10:36 AM EDT - 7 weeks ago

Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

Jun 23, 2025, 8:03 AM EDT - 7 weeks ago

Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy

Jun 18, 2025, 1:34 PM EDT - 2 months ago

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

Jun 18, 2025, 8:22 AM EDT - 2 months ago

Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway

Jun 16, 2025, 8:00 AM EDT - 2 months ago

Hoth Therapeutics to Attend 2025 BIO International Convention

Jun 12, 2025, 9:17 AM EDT - 2 months ago

Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases

Jun 11, 2025, 8:28 AM EDT - 2 months ago

Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities

Jun 5, 2025, 8:12 AM EDT - 2 months ago

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

May 12, 2025, 7:30 AM EDT - 3 months ago

Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

Apr 17, 2025, 8:01 AM EDT - 4 months ago

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Apr 15, 2025, 8:19 AM EDT - 4 months ago

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Apr 2, 2025, 8:02 AM EDT - 4 months ago

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Apr 2, 2025, 7:58 AM EDT - 4 months ago

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Mar 31, 2025, 4:45 PM EDT - 4 months ago

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Mar 26, 2025, 8:02 AM EDT - 5 months ago

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Mar 18, 2025, 8:06 AM EDT - 5 months ago

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Mar 10, 2025, 8:02 AM EDT - 5 months ago

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Mar 5, 2025, 1:40 PM EST - 5 months ago

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Mar 4, 2025, 8:16 AM EST - 5 months ago

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Feb 10, 2025, 8:22 AM EST - 6 months ago

Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic

Jan 24, 2025, 8:29 AM EST - 7 months ago

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

Jan 21, 2025, 8:29 AM EST - 7 months ago

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

Jan 17, 2025, 8:29 AM EST - 7 months ago

Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025

Jan 8, 2025, 1:27 PM EST - 7 months ago

Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries

Jan 7, 2025, 11:53 AM EST - 7 months ago

Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

Jan 7, 2025, 8:29 AM EST - 7 months ago

Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities

Dec 26, 2024, 7:58 AM EST - 8 months ago

Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment

Nov 20, 2024, 7:38 AM EST - 9 months ago

Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset

Oct 29, 2024, 12:43 PM EDT - 10 months ago

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Oct 15, 2024, 6:38 AM EDT - 10 months ago

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Sep 17, 2024, 7:57 AM EDT - 11 months ago

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Sep 5, 2024, 10:32 AM EDT - 1 year ago

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Sep 5, 2024, 8:03 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Aug 15, 2024, 8:04 AM EDT - 1 year ago

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Jul 16, 2024, 8:31 AM EDT - 1 year ago

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Jun 10, 2024, 8:11 AM EDT - 1 year ago

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

May 1, 2024, 8:00 AM EDT - 1 year ago

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Mar 27, 2024, 2:00 PM EDT - 1 year ago

Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds

Mar 27, 2024, 8:27 AM EDT - 1 year ago

Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

Mar 19, 2024, 8:21 AM EDT - 1 year ago

Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ

Feb 29, 2024, 8:38 AM EST - 1 year ago

Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio

Feb 26, 2024, 8:11 AM EST - 1 year ago

Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic

Feb 13, 2024, 11:45 AM EST - 1 year ago

Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024

Jan 18, 2024, 8:20 AM EST - 1 year ago

Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

Dec 5, 2023, 8:33 AM EST - 1 year ago

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Nov 14, 2023, 8:37 AM EST - 1 year ago

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

4trax Aug. 17 at 7:07 PM

$HOTH when is the next catalyst?

0 · Reply

canadianpennystockhunter Aug. 15 at 5:09 PM

0 · Reply

onestudy Aug. 15 at 4:23 PM

0 · Reply

PSM_EmpowerTrading Aug. 15 at 4:11 AM

1 · Reply

PSM_EmpowerTrading Aug. 14 at 7:01 PM

0 · Reply

PSM_EmpowerTrading Aug. 14 at 1:18 PM

0 · Reply

PSM_EmpowerTrading Aug. 14 at 4:23 AM

2 · Reply

Thunder000 Aug. 13 at 3:00 PM

1 · Reply

Pratik2024 Aug. 13 at 2:42 PM

$AREC $GFAI $HOTH $KULR $MWYN Which one to load now?

1 · Reply

PSM_EmpowerTrading Aug. 13 at 1:07 PM

0 · Reply

d_risk Aug. 13 at 5:41 AM

$HOTH - Hoth Therapeutics, Inc. - 10Q - Updated Risk Factors HOTH warns that evolving legislation and regulatory reforms could raise hurdles and costs for product approvals, impact pricing, and negatively affect business performance. #Biotechnology #Healthcare #LegislativeImpact #PricingPressure #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/HOTH/10-Q/2025-08-12

0 · Reply

PSM_EmpowerTrading Aug. 13 at 3:16 AM

🌅🌅 Watchlist part 2 ✅️ $BSLK low 3 support, if above 3.20, have potential to 3.70/.80, up on earnings ✅️ $CGTX low 1.20 support, if above 1.55, have potential to 1.75/.85 ✅️ $NIVF low 2 support, if above 2.40, have potential to 2.80/.90 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $HOTH $NUBV still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

WallStreetReporter Aug. 12 at 5:58 PM

$HOTH MOON TIME!!! get ready for #YUGE #ShortSqueeze at close!!! HAMMER TIME! #BREAKOUT #BREAKOUTSTOCKS

1 · Reply

Tino321 Aug. 12 at 5:48 PM

$HOTH let’s hit some previous highs already

0 · Reply

Alessandro437 Aug. 12 at 5:29 PM

$HOTH LFG 🚀☢️

0 · Reply

Pharma_Stock_Calls Aug. 12 at 4:32 PM

💊 New Signal: $HOTH 📥 Entry: $1.2100 💥 Suggested One-Shot: $1.3800 (Suggested – Optional) #stocksignals #HOTH

0 · Reply

Pratik2024 Aug. 12 at 2:18 PM

$AREC $GFAI $HOTH $KULR $MWYN Some big buy for MWYN

0 · Reply

beerboy85 Aug. 12 at 1:34 PM

$TNFA check it out. $PLRZ $HCTI $IXHL $HOTH

0 · Reply

PSM_EmpowerTrading Aug. 12 at 1:22 PM

🌅🌅 watchlist part 2 ✅️ $RMBL low 2 support, if above 2.60, have potential to 2.80/.90 ✅️ $EQ ideal if above 1 🚨🚨 The above tickers are not ideal for swing accumulation at current price 🎯 🎯 Ideal long stop loss if current support 🚫🚫 Avoid chasing long into strength near resistance ✅️ $HOTH $NUBV still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N not GR🥵🥵D

0 · Reply

WallStreetReporter Aug. 11 at 5:30 PM

NEW Stock LAUNCH TOMORROW 12:00PM! 🚀🚀🚀 will it be a #BANGER and DOUBLE within MINUTES? (just like $SYTA $SEGG $LTRY $HOTH $ADTX) 💰💰💰 What we LOVE: 🚀DEEP VALUE Below COMPS 🚀BEAUTIFUL #StockCharts w double bottom at 50&200 MA #ALGO trigger ready!! 🚀Market Cap under $10 Mil 🚀TIGHT float 🚀 previous high was +50X higher!!

1 · Reply

FastBull Aug. 11 at 5:14 PM

$HOTH

1 · Reply

JoseGilberto109 Aug. 8 at 11:21 PM

Wow what is happening to SNSE right now!? Seems like ALL volume and momentum are shifting into SNSE!! Could it be the next crazy runner of the day?? Only 500k float on SNSE - Bulls should keep it on watch!! Also watching: $ILAG $ITP $SYTA $HOTH !M

1 · Reply

Market Cap	16.97M
Revenue (ttm)	0.00
Net Income (ttm)	-8.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	188,800
Avg Vol	793,538
Day's Range	N/A - N/A
Shares Out	13.26M
Stochastic %K	54%
Beta	0.66
Analysts	Strong Sell
Price Target	$4.50